<DOC>
	<DOCNO>NCT03041025</DOCNO>
	<brief_summary>GSK2330811 humanize monoclonal antibody development systemic sclerosis ( SSc ) , rare autoimmune disease high morbidity mortality . Currently , approve disease modify therapy area high unmet medical need . GSK2330811 show bind neutralize Oncostatin M ( OSM ) associate fibrosis , vasculopathy inflammation number disease . This multi-center , randomize , double-blind ( sponsor open ) , placebo control , proof mechanism study first study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) repeat subcutaneous ( SC ) dose GSK2330811 male female participant diffuse cutaneous SSc ( dcSSc ) . Participants active disease disease duration &lt; = 60 month enrol . Approximately 24 40 participant randomize across two sequential cohort . Cohort 1 evaluate repeat-dose predict provide sub-maximal inhibition OSM , lead dose escalation decision . Cohort 1 plan consist least 4 participant , randomize 3 participant receive GSK2330811 100 milligram ( mg ) 1 receive placebo . Cohort 2 plan consist least 20 participant , randomize participant receive GSK2330811 300 mg placebo 3:1 ratio respectively . The duration study 34 week include screen period 6 week , treatment period 12 week follow-up period 16 week .</brief_summary>
	<brief_title>Proof Mechanism Study GSK2330811 Diffuse Cutaneous Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Participants 18 year , time signing informed consent . Documented diagnosis systemic sclerosis diffuse cutaneous involvement . Modified rodnan skin score ( mRSS ) &gt; =10 &lt; =35 screen . In case , disease duration &lt; =60 month screen , defined time onset first nonRaynaud 's phenomenon manifestation . Active disease define least one follow criterion screen : CReactive Protein ( CRP ) &gt; =6 mg/liter ( L ) ( 0.6 mg/deciliter [ dL ] ) , opinion investigator due SSc . Disease duration &lt; =18 month screen , define time first nonRaynaud 's phenomenon manifestation . Increase &gt; =3 mRSS unit , compare assessment perform within previous 6 month . Involvement one new body area increase &gt; =2 mRSS unit compare assessment perform within previous 6 month . Involvement two new body area within previous 6 month . An area uninvolved mildly thickened skin opinion investigator would allow subcutaneous injection either abdomen , front middle region thigh outer area upper arm . An area involve skin ( mRSS &gt; =1 ) forearm suitable repeat skin biopsy collect . Participants take mycophenolate mofetil ( &lt; =3,000 mg/day ) mycophenolate sodium ( &lt; =1,440 mg/day ) permit study participant stable dose &gt; =3 month first dose day ( Day 1 ) participant investigator willing continue dose least completion Day 85 ( Week 12 ) visit . Participants take oral corticosteroid ( &lt; =10 mg/day prednisone equivalent ) permit study participant receive dose great 10 mg/day least 4 week first dose day ( Day 1 ) investigator anticipate increase dose 10 mg/day study . Participants take phosphodiesterase 5 ( PDE5 ) inhibitor endothelin receptor antagonist ( include bosentan ) permit study participant stable dose least 4 week PDE5 inhibitor least 3 month endothelin antagonist first dose day ( Day 1 ) participant investigator willing continue dose least completion Day 85 ( Week 12 ) visit . Participants take permissible nonimmunosuppressive medication permit study ( e.g . hydroxychloroquine , angiotensin convert enzyme ( ACE ) inhibitors/angiotensin II receptor ( AR ) blocker , calciumchannel blocker protonpump inhibitor ) . However new longterm medication dosechanges exist long term medication permit two week prior first dose day ( Day 1 ) . Male participant must agree use contraception dose period least 126 day ( 18 week ) last dose study treatment refrain donate sperm period . A female participant eligible participate pregnant , breastfeeding , either woman childbearing potential ( WOCBP ) WOCBP agree use contraceptive 28 day prior first dose day ( Day 1 ) , dose period least 126 day ( 18 week ) last dose study treatment . Capable give sign informed consent include compliance requirement restriction study . Participants classify limited cutaneous SSc subset , determine investigator . Rheumatic autoimmune disease dcSSc include limited rheumatoid arthritis , systemic lupus erythematosus , mixed connective tissue disorder , polymyositis , dermatomyositis , systemic vasculitis primary Sjogren 's syndrome , determine investigator . Forced vital capacity ( FVC ) &lt; =50 percentage predict , diffuse capacity lung carbon dioxide ( DLCO ) ( correct hemoglobin ) &lt; =40 percentage predict screening . Pulmonary arterial hypertension , determine investigator . Clinically significant inflammatory myositis ( related SSc ) , determine investigator . SSc renal crisis within 6 month first day dose ( Day 1 ) . History clinically significant uncontrolled cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease screen related SSc opinion investigator would prevent participation study . Known bleed coagulation disorder . Major surgery ( include joint surgery ) within 3 month prior screen , plan duration study . Clinically significant multiple severe drug allergy ( include humanize monoclonal antibody ) , intolerance topical corticosteroid , severe posttreatment hypersensitivity reaction ( include , limited , erythema multiforme major , linear immunoglobulin A [ IgA ] dermatosis , toxic epidermal necrolysis , exfoliative dermatitis ) . An active infection , history infection follow : History opportunistic infection resolve 6 month prior first day dose ( Day1 ) recurrent infection determine investigator . This include infection may occur immunocompetent individual , fungal nail infection vaginal candidiasis , unless unusual severity frequency . A serious infection require treatment intravenous antibiotic and/or hospitalization , last dose antibiotic hospital discharge date within 3 month first day dose ( Day1 ) . An acute chronic infection require treatment oral antibiotic antiviral medication , last dose receive within 4 week first day dose ( Day1 ) . Any active unresolved bacterial , viral fungal infection present first day dose ( Day1 ) , whether require treatment . This include fungal nail infection . Active past osteomyelitis , unless fully resolve opinion investigator . Symptomatic herpes zoster resolve 3 month prior first day dose ( Day1 ) . History tuberculosis ( TB ) positive QuantiFERONTB Gold test screening . QuantiFERONTB Gold test indeterminate , repeat . A participant eligible unless second test negative negative tuberculin skin test ( define skin induration &lt; 5 millimeter [ mm ] 48 72 hour , regardless bacillus calmetteguerin vaccination history ) . There must clinical evidence TB physical examination participant ( screen examination ) . Alanine transferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) screening . Bilirubin &gt; 1.5 time ULN screening ( isolated bilirubin &gt; 1.5 time ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percentage ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception gilbert 's syndrome asymptomatic gallstone ) . QTc &gt; 480 millisecond ( msec ) QTc &gt; 500 msec participant bundle branch block screening . A history carcinoma situ malignant disease , exception basal cell carcinoma completely excise prior study . Treatment methotrexate within 3 month prior first dose day ( Day 1 ) . Previous plan bone marrow transplant ( e.g . autologous stem cell transplant ) . Treatment biologic within follow timeframes : Tocilizumab , abatacept anti tumor necrosis factor ( include etanercept , infliximab , certolizumab , golimumab adalimumab ) within 3 month prior first dose day ( Day 1 ) . Rituximab within 12 month prior first dose day ( Day 1 ) . For biologic consult medical monitor . Treatment oral intravenous cyclophosphamide within 6 month prior first dose day ( Day 1 ) . Treatment nonbiologic systemic immunosuppressive medication ( e.g . azathioprine , tacrolimus , ciclosporin ) mention within 4 week prior first dose day ( Day 1 ) , exception mycophenolate permit oral corticosteroid . Treatment topical immunosuppressive medication ( e.g . topical corticosteroid , tacrolimus ) within 1 week prior first dose day ( Day 1 ) . Treatment intravenous prostanoids ( e.g . iloprost ) within 2 week prior first dose day ( Day 1 ) plan treatment Day 85 ( Week 12 ) visit . Treatment antifibrotic medication include tyrosine kinase inhibitor ( e.g . nintedinib imatinib ) pirfenidone within 3 month prior first dose day ( Day 1 ) . Live vaccine ( ) within 4 week prior first dose day ( Day 1 ) , plan receive vaccine study . Treatment anticoagulant medication , include warfarin , heparin , thrombin inhibitor , factor Xa inhibitor within 2 week prior first dose day ( Day 1 ) . Treatment antiplatelet medication ( e.g . clopidogrel , prasugrel , ticagrelor dipyridamole ) within 2 week prior first dose day ( Day 1 ) . This include aspirin dos 150 mg less , nonsteroidal antiinflammatory drug , permit . Current enrollment past participation within last 30 day sign consent clinical study involve investigational study treatment . Exposure 4 new chemical entity within 12 month prior first dose day ( Day 1 ) . Any follow screening : Hemoglobin &lt; 110 gram ( g ) /L Platelet count &lt; 150x10^9/L Estimated glomerular filtration rate ( GFR ) ( modification diet renal disease [ MDRD ] calculation ) &lt; 45 mL/minute/1.73m^2 A positive human immunodeficiency virus ( HIV ) antibody test screening . Presence hepatitis B surface antigen ( HBsAg ) screening . Positive hepatitis B core antibody ( HBcAb ) test screening . Positive hepatitis C antibody test result screen within 3 month prior start study treatment . Positive hepatitis C ribonucleic acid ( RNA ) test result screen within 3 month prior first dose study treatment . Sensitivity study treatment component thereof , allergy opinion investigator , contraindicate participation study . Where participation study would result donation blood blood product excess volume 500 mL study . A history drug alcohol misuse could interfere participation trial accord protocol , opinion investigator impact physical mental wellbeing participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>Repeat-dose</keyword>
	<keyword>Phase IIA</keyword>
	<keyword>GSK2330811</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Proof mechanism study</keyword>
</DOC>